License lapse means Pfizer stops vaccine sales in China
As a result of the non-renewal of the license for its pneumococcal vaccine Prevenar by the Chinese authorities, US pharma giant Pfizer (NYSE: PFE) has said it will cease marketing the product in that country, according to reports by The Wall Street Journal and other media.
Pfizer said in a statement that the license for Prevenar, a vaccine that protects toddlers against pneumococcal disease that can lead to pneumonia and other infections, expired. “Based on a careful assessment of this situation, we have decided to cease our Vaccines commercial operations in China at this time, effective immediately,” the statement said.
Pfizer declined to explain why the Chinese import license for Prevenar had not been renewed. However, the company indicated that it would work with Chinese regulators to bring Prevenar 13 - an updated version of the vaccine - to market at some point in future.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze